Clinical Trial

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce these CAR+ T-cells and determine how well they work in the clinical setting.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-12-30; most recent amendment 2022-08-11.
Status change: Recruiting → Active, Not Recruiting 2022-08-11
Trial Details
NCT Number NCT04214886
Lead Sponsor Loyola University
Collaborators: Leukemia Research Foundation
Conditions B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Enrollment 24 participants
Start Date 2019-12-31
Primary Completion 2022-08-11 (estimated)
Study Completion 2034-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-08-15